Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial.
根據 SELECT 試驗,符合使用 semaglutide 的美國人群心血管事件減少情況。
Am Heart J 2024-08-25
US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events.
美國人口的資格和Semaglutide治療對肥胖盛行率和心血管疾病事件的預估影響。
Cardiovasc Drugs Ther 2023-08-14
Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial.
肥胖、心血管疾病,以及Semaglutide 的前景角色:SELECT 試驗的洞察。
Curr Probl Cardiol 2023-12-16
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
Semaglutide在肥胖和心血管疾病中的SELECT試驗中的長期腎臨床結果。
Nat Med 2024-05-25
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.
Semaglutide在SELECT研究中對基線HbA1c和HbA1c變化的超重或肥胖但無糖尿病人群的心血管結果。
Diabetes Care 2024-06-22
The cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetes.
在已有心血管疾病但無糖尿病的超重和肥胖人群中,semaglutide 降低心血管風險的成本效益。
Eur Heart J Qual Care Clin Outcomes 2024-08-03
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
Semaglutide 與肥胖及心臟衰竭患者的心血管結果:SELECT 試驗的預先指定分析。
Lancet 2024-08-24
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.
Semaglutide 對死亡率及 COVID-19 相關死亡的影響:來自 SELECT 試驗的分析。
J Am Coll Cardiol 2024-09-01